{"id":"W4285684531","doi":"10.14283/jpad.2022.48","title":"The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report","year":2022,"lang":"en","type":"article","venue":"The Journal of Prevention of Alzheimer s Disease","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alzheimer Society of Canada","funders":"Avid Radiopharmaceuticals; National Institutes of Health; Genentech; Grifols; H. Lundbeck A/S; National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; Novo Nordisk; Eisai; Prothena; Pfizer; Demensförbundet; Regeneron Pharmaceuticals; GHR Foundation; Danone; Biogen; AstraZeneca; Eli Lilly and Company; Amgen; Alzheimer's Drug Discovery Foundation; Sanofi; National Institute on Aging; Alzheimer's Association","keywords":"Clinical trial; Medicine; Dementia; Amyloid (mycology); Disease; Placebo; Task force; Cognitive decline; Oncology; Internal medicine; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.3176766,0.003456065,0.004979344,0.005128853,0.004870897,0.01983327,0.009431779,0.04323154,0.00681195],"category_scores_gemma":[0.21673,0.002993882,0.00727302,0.006172091,0.006279976,0.005970777,0.007628907,0.02151798,0.007613381],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0149889,"about_ca_system_score_gemma":0.08410197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01669459,"about_ca_topic_score_gemma":0.03012628,"domain_scores_codex":[0.8340093,0.06980614,0.02790342,0.005911882,0.05538752,0.006981814],"domain_scores_gemma":[0.5272329,0.2189781,0.0563484,0.01432558,0.131421,0.05169391],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00090696,0.0002201764,0.002998482,0.003103543,0.000298147,0.0002514416,0.0002150887,0.0008396706,0.0008418664,0.004062246,0.8771772,0.1090852],"study_design_scores_gemma":[0.001115826,0.0003513958,0.006134244,0.00902838,0.0004738303,0.0002785395,0.0001214967,0.001118397,0.0004410552,0.005221915,0.9755837,0.0001312009],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.002275961,0.1186324,0.009300475,0.7800134,0.05120504,0.005057514,0.00535913,0.0005284509,0.0276277],"genre_scores_gemma":[0.02625969,0.1401422,0.08387487,0.5571933,0.1019121,0.0277802,0.01481556,0.001091948,0.04693011],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.3176766,"threshold_uncertainty_score":0.8414263,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3964248221574626,"score_gpt":0.559941673221779,"score_spread":0.1635168510643164,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}